The category distinction between "brain exercise" and "brain training" sounds like semantic hair-splitting. It isn't. The two terms describe products that look similar — short daily cognitive tasks across thinking categories — but make fundamentally different promises about what the practice produces. The promise structure is what got the "brain training" category in regulatory trouble in the 2010s, and what makes the "brain exercise" framing the honest one in 2026.
The category split
Brain training, as a marketing category, accumulated a specific kind of claim:
- Practice will improve performance at school
- Practice will improve performance at work
- Practice will delay age-related cognitive decline
- Practice will reduce the effects of conditions like Alzheimer's, ADHD, PTSD
These are transfer claims — practice on the game produces improvement in untrained cognitive abilities or real-world performance. The 2016 FTC complaint against Lumos Labs (FTC press release) identified exactly these claims as "deceptive advertising," and the resulting $2 million settlement required Lumosity to notify subscribers and offer cancellation. The FTC's public statement noted that the brain-training industry had "preyed on consumers' fears about age-related cognitive decline."
Brain exercise, by contrast, is the narrower framing:
- Practice on a specific cognitive skill maintains that specific skill
- Skills you stop using get fewer reps
- Daily practice is one input among several into cognitive engagement
- No claims about transfer to untrained abilities or real-world performance
This is the claim structure the deliberate-practice literature (Ericsson, Krampe & Tesch-Römer, 1993) and the cognitive-offloading literature (Risko & Gilbert, 2016) actually support. It's narrower than "brain training" — and therefore defensible.
What the science consensus actually says
The two primary reference documents:
The 2014 Stanford-organised consensus statement, signed by over seventy cognitive scientists, concluded that "there is little evidence that playing brain games improves underlying broad cognitive abilities, or that it enables one to better navigate a complex realm of everyday life." Science magazine's coverage is the standard secondary reference.
The 2016 Simons et al. review in Psychological Science in the Public Interest titled "Do Brain-Training Programs Work?" — over 100 pages, hundreds of citations — surveyed the published evidence on commercial brain-training products and concluded:
- Near transfer is robust (improvement on the trained task)
- Far transfer is weak (generalisation to untrained tasks or real-world performance)
- The strongest evidence is the NIH ACTIVE Trial's speed-of-processing programme, now part of BrainHQ
The brain-exercise framing fits inside the "near transfer is robust" result. It doesn't need to claim more than what the literature supports.
What this means in practice
For the 2026 user, the category-split matters in three concrete ways:
1. What you can expect from the product. Brain exercise: maintain the practice habit on the cognitive surfaces you care about. Brain training (in the broad-claim sense): historically marketed cognitive uplift the evidence doesn't support. The 2026 brain-training products are more careful than their 2014 marketing, but the category history is real.
2. Where the regulatory line is. The FTC drew the line at broad cognitive-uplift marketing claims in 2016. Products that stay on the brain-exercise side of the line (narrower promises) haven't drawn equivalent regulatory action. Senwitt is on that side by design.
3. Which product fits which user. If your interest is "practise specific thinking skills daily," brain-exercise products fit. If your interest is "prevent cognitive decline," no current commercial product has the evidence to credibly promise that — your time is better spent on the broader lifestyle behaviours the NIH cognitive-health page lists.
The one notable exception
BrainHQ's speed-of-processing programme is the one current commercial product with peer-reviewed evidence of real-world transfer — specifically, the NIH-funded ACTIVE Trial showed older adults reported less difficulty with instrumental activities of daily living ten years after a short training course. The effect is narrow (older adults, processing-speed specifically) and the strongest claims have been contested, but it's the cleanest existing exception. The BrainHQ comparison page covers this honestly.
For everyone else, the brain-exercise framing is the defensible one.
How Senwitt sits inside this
Senwitt's marketing — across the pricing page, the scope-of-evidence page, every research page, every comparison page — uses brain-exercise language and avoids brain-training language deliberately. The site explicitly disclaims:
- IQ improvement claims
- Cognitive-decline prevention claims
- Medical claims of any kind
- Transfer-to-real-world-outcomes claims
The config/proof.ts file is intentionally empty — no fake testimonials, no inflated install counts, no placeholder ratings. The category sits where the evidence sits.
For the longer argument, the research/brain-exercise-vs-brain-training page is the canonical treatment. The research/does-brain-training-work page is the focused review of the historical claim structure.
Why the category split is more than vocabulary
A useful piece of context for readers who think the distinction is a marketing dodge — of course Senwitt would call it brain exercise; brain training is the term that got into trouble. The distinction is older than the 2010s marketing problem and predates the FTC case by decades. The deliberate-practice literature has, since Ericsson's 1993 paper, drawn a sharp line between practice on the specific task (near transfer is robust) and the implied generalisation to broad cognitive capability (far transfer is weak). The 2014 Stanford consensus and the 2016 Simons review are formal restatements of that distinction in the context of a consumer category that had quietly let the line drift. The brain-exercise framing is not a rebrand. It is the published-evidence-aligned version of what the category can honestly claim, with the broader promises removed because the evidence never supported them.
What changes about the practice itself
Practically, almost nothing. The daily session looks similar in both framings — short, mixed, on a screen, across cognitive surfaces. The deliberate-practice frame inherits all the same operational design choices the habit-design literature supports: bounded daily ask, low activation cost, forgiveness on missed days, a streak that does not punish. The brain-exercise framing changes how the product describes what the daily session is for, not what the daily session is. The shift matters at the level of expectation-setting and at the level of FTC compliance. The user shows up to maintain a set of specific cognitive surfaces in regular use. The product is honest about not claiming more than that. The literature supports the smaller pitch. Everyone's interests align — the user, the regulator, the published evidence — when the language matches what the practice actually does.
A note on what stays out of bounds
Three claim types remain out of bounds for the brain-exercise framing regardless of how the underlying tech evolves. Broad cognitive-uplift transfer. Cognitive-decline prevention. Medical or quasi-medical effects. These are not areas where the evidence is thin and might one day support the claim; they are areas where the FTC and the published scientific consensus have explicitly drawn lines. The honest brain-exercise pitch lives strictly inside the smaller envelope of "practice on a specific cognitive skill maintains that specific skill," and any temptation to drift past that envelope is a product-strategy mistake whether the literature changes or not. Discipline about the claim line is the structural defence that lets the daily practice survive the next regulatory cycle, the next adverse headline, and the next round of category-wide marketing pushback.
